Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results

Paul G. Richardson, William I. Bensinger, Carol Ann Huff, Caitlin L. Costello, Nikoletta Lendvai, Jesus G. Berdeja, Larry D. Anderson, David S. Siegel, Daniel Lebovic, Sundar Jagannath, Jacob P. Laubach, Keith E. Stockerl-Goldstein, Long Kwei, Fong Clow, Laurence Elias, Zeena Salman, Thorsten Graef, Elizabeth Bilotti, Ravi Vij

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Novel therapies with unique new targets are needed for patients who are relapsed/refractory to current treatments for multiple myeloma. Ibrutinib is a first-in-class, once-daily, oral covalent inhibitor of Bruton tyrosine kinase, which is overexpressed in the myeloma stem cell population. This study examined various doses of ibrutinib ± low-dose dexamethasone in patients who received ≥2 prior lines of therapy, including an immunomodulatory agent. Daily ibrutinib ± weekly dexamethasone 40 mg was assessed in 4 cohorts using a Simon 2-stage design. The primary objective was clinical benefit rate (CBR; ≥minimal response); secondary objectives included safety. Patients (n = 92) received a median of 4 prior regimens. Ibrutinib + dexamethasone produced the highest CBR (28%) in Cohort 4 (840 mg + dexamethasone; n = 43), with median duration of 9·2 months (range, 3·0–14·7). Progression-free survival was 4·6 months (range, 0·4–17·3). Grade 3–4 haematological adverse events included anaemia (16%), thrombocytopenia (11%), and neutropenia (2%); grade 3–4 non-haematological adverse events included pneumonia (7%), syncope (3%) and urinary tract infection (3%). Ibrutinib + dexamethasone produced notable responses in this heavily pre-treated population. The encouraging efficacy, coupled with the favourable safety and tolerability profile of ibrutinib, supports its further evaluation as part of combination treatment.

Original languageEnglish (US)
Pages (from-to)821-830
Number of pages10
JournalBritish Journal of Haematology
Volume180
Issue number6
DOIs
StatePublished - Mar 1 2018

Fingerprint

Multiple Myeloma
Dexamethasone
Safety
Immunomodulation
Syncope
Neutropenia
Urinary Tract Infections
Thrombocytopenia
Population
Disease-Free Survival
Anemia
Pneumonia
Stem Cells
Therapeutics
PCI 32765

Keywords

  • Bruton tyrosine kinase
  • dexamethasone
  • ibrutinib
  • multiple myeloma

ASJC Scopus subject areas

  • Hematology

Cite this

Richardson, P. G., Bensinger, W. I., Huff, C. A., Costello, C. L., Lendvai, N., Berdeja, J. G., ... Vij, R. (2018). Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. British Journal of Haematology, 180(6), 821-830. https://doi.org/10.1111/bjh.15058

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma : phase 2 trial results. / Richardson, Paul G.; Bensinger, William I.; Huff, Carol Ann; Costello, Caitlin L.; Lendvai, Nikoletta; Berdeja, Jesus G.; Anderson, Larry D.; Siegel, David S.; Lebovic, Daniel; Jagannath, Sundar; Laubach, Jacob P.; Stockerl-Goldstein, Keith E.; Kwei, Long; Clow, Fong; Elias, Laurence; Salman, Zeena; Graef, Thorsten; Bilotti, Elizabeth; Vij, Ravi.

In: British Journal of Haematology, Vol. 180, No. 6, 01.03.2018, p. 821-830.

Research output: Contribution to journalArticle

Richardson, PG, Bensinger, WI, Huff, CA, Costello, CL, Lendvai, N, Berdeja, JG, Anderson, LD, Siegel, DS, Lebovic, D, Jagannath, S, Laubach, JP, Stockerl-Goldstein, KE, Kwei, L, Clow, F, Elias, L, Salman, Z, Graef, T, Bilotti, E & Vij, R 2018, 'Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results', British Journal of Haematology, vol. 180, no. 6, pp. 821-830. https://doi.org/10.1111/bjh.15058
Richardson, Paul G. ; Bensinger, William I. ; Huff, Carol Ann ; Costello, Caitlin L. ; Lendvai, Nikoletta ; Berdeja, Jesus G. ; Anderson, Larry D. ; Siegel, David S. ; Lebovic, Daniel ; Jagannath, Sundar ; Laubach, Jacob P. ; Stockerl-Goldstein, Keith E. ; Kwei, Long ; Clow, Fong ; Elias, Laurence ; Salman, Zeena ; Graef, Thorsten ; Bilotti, Elizabeth ; Vij, Ravi. / Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma : phase 2 trial results. In: British Journal of Haematology. 2018 ; Vol. 180, No. 6. pp. 821-830.
@article{b0091d9fa7eb41ba839d05e28c83c1ea,
title = "Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results",
abstract = "Novel therapies with unique new targets are needed for patients who are relapsed/refractory to current treatments for multiple myeloma. Ibrutinib is a first-in-class, once-daily, oral covalent inhibitor of Bruton tyrosine kinase, which is overexpressed in the myeloma stem cell population. This study examined various doses of ibrutinib ± low-dose dexamethasone in patients who received ≥2 prior lines of therapy, including an immunomodulatory agent. Daily ibrutinib ± weekly dexamethasone 40 mg was assessed in 4 cohorts using a Simon 2-stage design. The primary objective was clinical benefit rate (CBR; ≥minimal response); secondary objectives included safety. Patients (n = 92) received a median of 4 prior regimens. Ibrutinib + dexamethasone produced the highest CBR (28{\%}) in Cohort 4 (840 mg + dexamethasone; n = 43), with median duration of 9·2 months (range, 3·0–14·7). Progression-free survival was 4·6 months (range, 0·4–17·3). Grade 3–4 haematological adverse events included anaemia (16{\%}), thrombocytopenia (11{\%}), and neutropenia (2{\%}); grade 3–4 non-haematological adverse events included pneumonia (7{\%}), syncope (3{\%}) and urinary tract infection (3{\%}). Ibrutinib + dexamethasone produced notable responses in this heavily pre-treated population. The encouraging efficacy, coupled with the favourable safety and tolerability profile of ibrutinib, supports its further evaluation as part of combination treatment.",
keywords = "Bruton tyrosine kinase, dexamethasone, ibrutinib, multiple myeloma",
author = "Richardson, {Paul G.} and Bensinger, {William I.} and Huff, {Carol Ann} and Costello, {Caitlin L.} and Nikoletta Lendvai and Berdeja, {Jesus G.} and Anderson, {Larry D.} and Siegel, {David S.} and Daniel Lebovic and Sundar Jagannath and Laubach, {Jacob P.} and Stockerl-Goldstein, {Keith E.} and Long Kwei and Fong Clow and Laurence Elias and Zeena Salman and Thorsten Graef and Elizabeth Bilotti and Ravi Vij",
year = "2018",
month = "3",
day = "1",
doi = "10.1111/bjh.15058",
language = "English (US)",
volume = "180",
pages = "821--830",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma

T2 - phase 2 trial results

AU - Richardson, Paul G.

AU - Bensinger, William I.

AU - Huff, Carol Ann

AU - Costello, Caitlin L.

AU - Lendvai, Nikoletta

AU - Berdeja, Jesus G.

AU - Anderson, Larry D.

AU - Siegel, David S.

AU - Lebovic, Daniel

AU - Jagannath, Sundar

AU - Laubach, Jacob P.

AU - Stockerl-Goldstein, Keith E.

AU - Kwei, Long

AU - Clow, Fong

AU - Elias, Laurence

AU - Salman, Zeena

AU - Graef, Thorsten

AU - Bilotti, Elizabeth

AU - Vij, Ravi

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Novel therapies with unique new targets are needed for patients who are relapsed/refractory to current treatments for multiple myeloma. Ibrutinib is a first-in-class, once-daily, oral covalent inhibitor of Bruton tyrosine kinase, which is overexpressed in the myeloma stem cell population. This study examined various doses of ibrutinib ± low-dose dexamethasone in patients who received ≥2 prior lines of therapy, including an immunomodulatory agent. Daily ibrutinib ± weekly dexamethasone 40 mg was assessed in 4 cohorts using a Simon 2-stage design. The primary objective was clinical benefit rate (CBR; ≥minimal response); secondary objectives included safety. Patients (n = 92) received a median of 4 prior regimens. Ibrutinib + dexamethasone produced the highest CBR (28%) in Cohort 4 (840 mg + dexamethasone; n = 43), with median duration of 9·2 months (range, 3·0–14·7). Progression-free survival was 4·6 months (range, 0·4–17·3). Grade 3–4 haematological adverse events included anaemia (16%), thrombocytopenia (11%), and neutropenia (2%); grade 3–4 non-haematological adverse events included pneumonia (7%), syncope (3%) and urinary tract infection (3%). Ibrutinib + dexamethasone produced notable responses in this heavily pre-treated population. The encouraging efficacy, coupled with the favourable safety and tolerability profile of ibrutinib, supports its further evaluation as part of combination treatment.

AB - Novel therapies with unique new targets are needed for patients who are relapsed/refractory to current treatments for multiple myeloma. Ibrutinib is a first-in-class, once-daily, oral covalent inhibitor of Bruton tyrosine kinase, which is overexpressed in the myeloma stem cell population. This study examined various doses of ibrutinib ± low-dose dexamethasone in patients who received ≥2 prior lines of therapy, including an immunomodulatory agent. Daily ibrutinib ± weekly dexamethasone 40 mg was assessed in 4 cohorts using a Simon 2-stage design. The primary objective was clinical benefit rate (CBR; ≥minimal response); secondary objectives included safety. Patients (n = 92) received a median of 4 prior regimens. Ibrutinib + dexamethasone produced the highest CBR (28%) in Cohort 4 (840 mg + dexamethasone; n = 43), with median duration of 9·2 months (range, 3·0–14·7). Progression-free survival was 4·6 months (range, 0·4–17·3). Grade 3–4 haematological adverse events included anaemia (16%), thrombocytopenia (11%), and neutropenia (2%); grade 3–4 non-haematological adverse events included pneumonia (7%), syncope (3%) and urinary tract infection (3%). Ibrutinib + dexamethasone produced notable responses in this heavily pre-treated population. The encouraging efficacy, coupled with the favourable safety and tolerability profile of ibrutinib, supports its further evaluation as part of combination treatment.

KW - Bruton tyrosine kinase

KW - dexamethasone

KW - ibrutinib

KW - multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=85041814297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041814297&partnerID=8YFLogxK

U2 - 10.1111/bjh.15058

DO - 10.1111/bjh.15058

M3 - Article

C2 - 29435979

AN - SCOPUS:85041814297

VL - 180

SP - 821

EP - 830

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 6

ER -